Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin/Fluoxetine Combination for Overweight and Obesity
NCT03051451Phase 2Suspended
- Sponsor
- Laboratorios Silanes
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liquid metformin (Aspargo Labs) and fluoxetine in obesity and Overweight (3 arms), sponsored by Laboratorios Silanes. Primary endpoint: Decrease of at least 5% of body weight and the reduction in the body mass index at 6 months. Status: suspended.
02
Drugs
liquid metformin (Aspargo Labs)fluoxetine
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03051451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051451.